Please use this identifier to cite or link to this item:
|Title:||Transdisciplinarity in strategic decisions for oncological treatments|
Rueff, M. C.
|Publisher:||World Association for Medical Law|
|Abstract:||The current models for equity and access to new oncological treatments are under strain due to the economic and demographic crisis in Europe as well as the rising costs of innovative drugs. Cancer treatment needs a model of patient-centered care in which an interdisciplinary care plan, based on evidence-based practice is essential for patient wellbeing. Physicians should be focused in the doctor-patient relationship and informed consent is important especially when new medicines are prescribed. Related with informed consent there is therapeutic privilege. Moreover, utilitarianism and social justice has to be considered without compromising human dignity and the principle of economy cannot be ignored in the provision of public services. An interdisciplinary approach is essential for the new oncological drugs approval. Therefore, transdisciplinary decision between civil society, pharmaceuticals, healthcare professionals and policymakers is essential in order to assure quality, access to innovation and equity in oncological care.|
|Appears in Collections:||BRU-RI - Artigo em revista científica internacional com arbitragem científica|
Files in This Item:
|post_print_Artigo_B___Transdiciplinary_.pdf||253.78 kB||Adobe PDF||View/Open Request a copy|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.